Breast Cancer — Research Intelligence Dashboard
Prototype dashboard for architecture validation. Metrics shown are illustrative until registry enrichment and GRMI calculation engine are live.
Executive Summary
Data snapshot: February 2026
846
Total Active Trials
ClinicalTrials.gov Registry Subset
264
New Trials
Rolling 12 Months
21.0%
Phase I Density
Percentage
47
Distinct Biomarkers
Active
Accelerating
Research Momentum Classification (Rolling 12-Month Model)
Global Research Momentum Index (GRMI)
94
GRMI ScoreComposite index weighted as:
• Trial Velocity (30%)
• Early-Phase Density (25%)
• Biomarker Diversity (20%)
• Modality Expansion (15%)
• Geographic Spread (10%)
• Trial Velocity (30%)
• Early-Phase Density (25%)
• Biomarker Diversity (20%)
• Modality Expansion (15%)
• Geographic Spread (10%)
Accelerating
12-Month Trend
Component Breakdown
96
Trial Velocity Score
89
Early Phase Density
97
Biomarker Diversity
93
Modality Expansion
94
Geographic Spread
Phase & Modality Distribution
Phase Distribution
Modality Distribution
Geographic Spread
52
Countries Active
412
United States
Active Trials
289
Europe
Active Trials
145
Asia-Pacific
Active Trials
12-Month Geographic Expansion:+7 new countries, +94 new trial sites
Centers Actively Studying This Area
Institutions listed based on active breast cancer trial count ≥ 35 (ClinicalTrials.gov registry analysis).
| Institution Name | Active Trials | Phase I % | Dominant Modality | Distinct Biomarkers |
|---|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 64 | 29% | ADC | 24 |
| Dana-Farber Cancer Institute | 58 | 31% | Targeted Therapy | 22 |
| MD Anderson Cancer Center | 67 | 35% | Combination | 26 |
| Mayo Clinic | 41 | 24% | Targeted Therapy | 18 |
| Yale Cancer Center | 37 | 27% | ADC | 17 |
| University of Pennsylvania | 39 | 33% | Immunotherapy | 19 |
Institutional Research Footprint Overlay
Institutional Overlay (Phase II Modeling)
This section will display global baseline vs. selected institution metrics side-by-side, enabling comparative analysis of institutional research positioning.
What This Signals
ADC ecosystem expanding rapidly
Antibody-drug conjugate trials increased 89% year-over-year, reflecting HER2-low validation
Biomarker heterogeneity increasing
47 distinct biomarkers active, including ESR1, PIK3CA, BRCA mutations beyond traditional markers
Immunotherapy subset stratification
Triple-negative breast cancer (TNBC) immunotherapy trials increased 54%, reflecting PD-L1 validation
Combination therapy density high
203 combination trials active, testing multi-agent strategies across receptor subtypes